Sanofi presents positive data on cancer drug

Sanofi-Aventis has presented data from a late stage trial of its S-1 stomach cancer drug which showed a significant drop in the risk of death from early stage gastric cancer cases when compared to patients who were treated only with surgery. S-1, which Sanofi-Aventis is developing with Japan's Taiho Pharmaceutical, reduced the risk of death by 32 percent. Fewer than six percent of the patients taking the drug experienced side effects. Overall survival at 3 years was 80.5 percent for patients receiving S-1 and 70.1 percent for patients undergoing surgery alone. S-1 is approved for a number of cancer indications in Japan but hasn't been approved yet by the FDA.

- check out the release
- here's the report on the data from AFX

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.